Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$9.48
HK$0.16(3.97%)
At close: 4:00 PM EST
HK$9.48
HK$0.16(3.97%)
Day’s Range― - ―
52-Week RangeHK$6.70 - HK$11.98
Previous CloseN/A
Volume216.80K
Average Volume (3M)805.10K
Market Cap
HK$4.26B
Enterprise ValueHK$2.86K
Total Cash (Recent Filing)HK$527.63M
Total Debt (Recent Filing)HK$47.38M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
Revenue Ramp / CommercializationA rapid revenue ramp to ~88.2M demonstrates the company has moved from development to commercial sales, indicating product adoption and distribution progress. This structural commercialization reduces execution risk and lays groundwork for operating leverage as volumes grow over months.
High Gross MarginsA ~75% gross margin signals attractive unit economics for its transcatheter devices, implying that incremental sales generate strong contribution margins. Durable high margins allow reinvestment in R&D and commercialization and provide resilience to pricing pressure as scale improves.
Low Financial LeverageVery low debt-to-equity (~0.06) reduces solvency risk and preserves financial flexibility. With limited fixed financial obligations, the company has structural capacity to raise capital or sustain investment in growth without immediate refinancing pressure, important while profitability is developing.
Bears Say
Large Net LossesA net loss of ~264.2M far exceeds current revenue, showing operating expenses and investment run-rate materially outpace sales. Persistently large losses are a structural constraint on shareholder value, likely necessitating material cost control or external financing to reach sustainable profitability.
Negative Cash Flow / Cash BurnSustained negative OCF and FCF indicate the business consumes cash to operate and invest. Although burn improved versus prior years, continued negative cash generation creates ongoing funding needs, increasing the probability of dilutive capital raises or constrained investment over the next several quarters.
Negative Returns On EquityROE near -33% means shareholder capital is currently being eroded rather than grown. This structural lack of profitability signals weak returns on invested capital and may pressure management to alter strategy, reduce expenditures, or seek additional funding to prevent further equity dilution.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$6.70 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$4.26B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 46 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.29 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.35%
12-Months-Change
Fundamentals
Return on Equity
-22.25%
Trailing 12-Months
Asset Growth
-8.72%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―